By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Syros Pharmaceuticals 

480 Arsenal Street
Suite 130
Watertown  Massachusetts  02472  U.S.A.
Phone: 617-744-1340 Fax: n/a


We are a therapeutics company passionately committed to applying our scientific leadership in the emerging field of gene control to transform the lives of patients with cancer and other diseases.

Founded by world-leading experts in gene regulation, and led by a seasoned management team, Syros is focused on developing new medicines that control genes that cause disease. Central to our approach is a proprietary drug development platform of integrated gene control assay technologies, computational biology, chemistry, and deep biologic insights that gives us an unprecedented understanding of and control over gene regulation. Our pioneering research and drug development capabilities provide us with the distinctive ability to identify new, important disease and patient-targeted gene control medicines.

Key Statistics

Ownership: Private

Web Site: Syros Pharma


Company News
Syros Pharma To Present At BioCentury NewsMakers Conference 8/26/2016 9:11:23 AM
Syros Pharma Reports Second Quarter 2016 Financial Results And Provides Business Update 8/15/2016 12:04:35 PM
Syros Pharma To Present At Wedbush PacGrow Healthcare Conference 8/3/2016 11:08:10 AM
Cambridge-Based Syros Pharma Gets $50M in Market Debut 6/30/2016 7:08:50 AM
Syros Pharmaceuticals Plans to Take the IPO Plunge Despite Brexit Uncertainty 6/27/2016 6:50:39 AM
Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity Of Its Lead Drug Candidates At 21st Congress Of The European Hematology Association 6/10/2016 8:17:03 AM
Syros Pharmaceuticals Appoints Industry Leader Sanj K. Patel To Its Board Of Directors 6/1/2016 4:40:14 PM
Syros Pharmaceuticals Announces FDA Acceptance Of IND To Advance SY-1425 Into Phase II Clinical Trial 5/31/2016 10:56:09 AM
Syros Pharmaceuticals To Present On Its Two Lead Programs, SY-1425 And SY-1365, At 21st Congress Of The European Hematology Association 5/19/2016 12:11:16 PM
Syros Pharmaceuticals Presents New Data Demonstrating Significant Anti-Tumor Activity Of Its Selective CDK7 Inhibitor In Preclinical Models Of Acute Myeloid Leukemia 4/20/2016 11:28:30 AM